Description
While the study adjusts for APOE ε4 status, it doesn’t explore potential gene-gene interactions between BIN1 variants and APOE ε4. Given both are major LOAD risk factors, their interaction could reveal population-specific risk mechanisms.
Gap type: open_question Source paper: Genetic variation in BIN1 gene and Alzheimer’s disease risk in Han Chinese individuals. (2014, Neurobiology of aging, PMID:24582639)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:51.055536+00:00”, “resolution_summary”: “Resolved by hypothesis h-26353f7f59: Temporal order is subtype-specific rather than universal. Supporting evidence includes debate sess_SDA-2026-04-14-gap-pubmed-20260410-180532-e8930cb8.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-26353f7f59”, “title”: “Temporal order is subtype-specific rather than universal”, “score”: 0.3, “reason”: “2 token overlaps; entity overlap: apoe, bin1”, “analysis_id”: “SDA-2026-04-25-gapdebate-e849205bca”, “target_gene”: “APOE, SORL1, NTRK1, BIN1, PICALM”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.73, “confidence_score”: 0.76, “status”: “proposed”, “pubmed_evidence_ids”: [“28894304”, “31367008”, “34815562”, “36348357”, “37086935”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-180532-e8930cb8”, “title”: “The abstract shows V1613M variant reduces amyloid plaques and damage in 5xFAD mice, yet ABCA7 loss-of-function mutations increase LOAD risk. This apparent contradiction suggests complex genotype-phenotype relationships that could inform therapeutic targeting.\n\nGap type: contradiction\nSource paper: The Abca7 (None, None, PMID:38506634)”, “score”: 0.434, “reason”: “6 token overlaps; entity overlap: load, pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-180532-e8930cb8”, “quality_score”: 0.6, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-184126-b2c3e2e8”, “title”: “This study shows APOE4 carriers have enhanced beneficial innate immune responses, directly contradicting the established view of APOE4 as purely detrimental in neurodegeneration. This paradox challenges fundamental assumptions about APOE4’s role in AD pathogenesis.\n\nGap type: contradiction\nSource paper: APOE genotype-specific differences in the innate immune response (2021, JAMA Neurology, PMID:33432245)”, “score”: 0.399, “reason”: “5 token overlaps; entity overlap: apoe, pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-184126-b2c3e2e8”, “quality_score”: 0.6, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1_task_9aae8fc5”, “title”: “The abstract identifies APOE4 association with increased TDP-43 pathology but the mechanistic link is unexplained. This connection could reveal novel therapeutic targets since APOE4 is the strongest genetic risk factor for AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.387, “reason”: “8 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1”, “quality_score”: 0.61, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-185318-186b0446”, “title”: “The abstract explicitly states the critical need to identify genetic risk factors for CTE, but these remain unknown. Understanding genetic susceptibility could enable risk stratification and personalized prevention strategies for athletes and military personnel.\n\nGap type: open_question\nSource paper: The neuropathology of chronic traumatic encephalopathy. (2015, Brain pathology (Zurich, Switzerland), PMID:25904048)”, “score”: 0.366, “reason”: “8 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-185318-186b0446”, “quality_score”: 0.58, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731”, “title”: “The abstract identifies BACE1 as an attractive drug target but doesn’t address its normal physiological roles. Understanding these functions is critical to predict potential adverse effects of BACE1 inhibitors in therapeutic development.\n\nGap type: open_question\nSource paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)”, “score”: 0.358, “reason”: “7 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}